Toll Free: 1-888-928-9744

Traveler's Diarrhea - Pipeline Review, H1 2016

Published: Mar 30, 2016 | Pages: 60 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Traveler's Diarrhea - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Traveler's Diarrhea - Pipeline Review, H1 2016', provides an overview of the Traveler's Diarrhea pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Traveler's Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler's Diarrhea and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Traveler's Diarrhea
- The report reviews pipeline therapeutics for Traveler's Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Traveler's Diarrhea therapeutics and enlists all their major and minor projects
- The report assesses Traveler's Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Traveler's Diarrhea

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Traveler's Diarrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Traveler's Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Traveler's Diarrhea Overview 7 Therapeutics Development 8 Pipeline Products for Traveler's Diarrhea - Overview 8 Pipeline Products for Traveler's Diarrhea - Comparative Analysis 9 Traveler's Diarrhea - Therapeutics under Development by Companies 10 Traveler's Diarrhea - Therapeutics under Investigation by Universities/Institutes 11 Traveler's Diarrhea - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Traveler's Diarrhea - Products under Development by Companies 15 Traveler's Diarrhea - Products under Investigation by Universities/Institutes 16 Traveler's Diarrhea - Companies Involved in Therapeutics Development 17 Chiesi Farmaceutici SpA 17 Cosmo Pharmaceuticals S.p.A 18 GlaxoSmithKline Plc 19 Nippon Shinyaku Co., Ltd. 20 Prokarium Limited 21 Scandinavian Biopharma Holding AB 22 Sigmoid Pharma Limited 23 Traveler's Diarrhea - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 ACE-527 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 ACE-920 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Etvax - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 GVXNSD-133 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 IMSUTMR-1501 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 prulifloxacin - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 rifamycin CR - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Typhetec - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Vaccine for Traveler's Diarrhea - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Traveler's Diarrhea - Recent Pipeline Updates 48 Traveler's Diarrhea - Discontinued Products 51 Traveler's Diarrhea - Product Development Milestones 52 Featured News & Press Releases 52 Oct 04, 2013: Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers' Diarrhea 52 Sep 11, 2012: Santarus Announces Positive Top-Line Phase III Results For Rifamycin SV MMX In Travelers' Diarrhea 53 Aug 17, 2011: TD Vaccines To Present ACE527 Phase II Data At Sachs 11th Annual Biotech In Europe 54 Sep 14, 2009: Data From Optimers Second Phase III Study of Prulifloxacin Presented At Annual Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 54 Sep 02, 2009: Optimer Pharmaceuticals Announces Presentations Of Additional Phase III Prulifloxacin Data At Upcoming ICAAC Annual Meeting 55 Feb 26, 2009: Optimer Pharmaceuticals Announces Publication In Peer-Reviewed Journal About Prulifloxacins Antibacterial Activity Against Infectious Diarrhea Producing Bacteria 56 Feb 24, 2009: Optimer Pharmaceuticals Announces Positive Results From Second Phase III Study Of Prulifloxacin For Infectious Diarrhea In Travelers 56 Oct 20, 2008: Data from Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea Presented At ICAAC/IDSA Annual Meeting 57 Sep 02, 2008: Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase III Clinical Trial 58 Jul 16, 2008: Optimer Pharmaceuticals Announces Positive Results In Prulifloxacin Phase III Study 58 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables
Number of Products under Development for Traveler's Diarrhea, H1 2016 8 Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Traveler's Diarrhea - Pipeline by Chiesi Farmaceutici SpA, H1 2016 17 Traveler's Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2016 18 Traveler's Diarrhea - Pipeline by GlaxoSmithKline Plc, H1 2016 19 Traveler's Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 20 Traveler's Diarrhea - Pipeline by Prokarium Limited, H1 2016 21 Traveler's Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H1 2016 22 Traveler's Diarrhea - Pipeline by Sigmoid Pharma Limited, H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Traveler's Diarrhea Therapeutics - Recent Pipeline Updates, H1 2016 48 Traveler's Diarrhea - Discontinued Products, H1 2016 51


List of Figures
Number of Products under Development for Traveler's Diarrhea, H1 2016 8 Number of Products under Development for Traveler's Diarrhea - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Targets, H1 2016 25 Number of Products by Stage and Targets, H1 2016 25 Number of Products by Mechanism of Actions, H1 2016 27 Number of Products by Stage and Mechanism of Actions, H1 2016 27 Number of Products by Routes of Administration, H1 2016 29 Number of Products by Stage and Routes of Administration, H1 2016 29 Number of Products by Molecule Types, H1 2016 31 Number of Products by Stage and Molecule Types, H1 2016 31

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast period

Read More...

Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to dri

Read More...

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify